Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Caspofungin
Drug ID BADD_D00376
Description Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Indications and Usage For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Marketing Status Prescription
ATC Code J02AX04
DrugBank ID DB00520
KEGG ID D07626
MeSH ID D000077336
PubChem ID 2826718
TTD Drug ID D00ZCN
NDC Product Code Not Available
Synonyms Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate
Chemical Information
Molecular Formula C52H88N10O15
CAS Registry Number 162808-62-0
SMILES CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O) C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypokalaemia14.05.03.0020.000705%
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.000184%Not Available
Influenza like illness08.01.03.010--
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site phlebitis24.05.03.003; 12.07.03.012; 08.02.03.011--Not Available
Insomnia19.02.01.002; 17.15.03.002--
International normalised ratio increased13.01.02.008--
Interstitial lung disease22.01.02.003; 10.02.01.0330.000184%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lacrimation increased06.08.02.004--
Laryngeal pain22.02.05.036--
Laryngospasm22.04.02.002--
Liver disorder09.01.08.0010.003172%Not Available
Local reaction08.01.03.012--Not Available
Lung disorder22.02.07.0010.000184%Not Available
Lymphocyte count decreased13.01.06.006--
Lymphocyte count increased13.01.06.007--
Lymphoma16.20.01.001; 01.12.01.0010.000276%Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Metabolic acidosis14.01.01.003--Not Available
Mucormycosis11.03.05.011; 07.05.07.011; 22.07.03.021; 17.06.09.0030.000184%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages